News MIT team develops 'years-long' drug delivery tech Researchers in the US have devised a new depot system that could provide months or even years of delivery from a single subcutaneous injection.
News Novo Nordisk looks east for another obesity therapy Novo Nordisk has moved to shore up its obesity pipeline with a $2bn licensing deal for a triple agonist developed by China's United Biotechnology.
News Phase 3 readout puts Opthea at risk of insolvency After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.
News Augustine decloaks with $85m for nerve disease programme Belgian start-up Augustine raises €78m ($85m) in first-round funding for HDAC6 inhibitors headed by a candidate for Charcot-Marie-Tooth disease.
News 23andMe files for bankruptcy protection DNA testing specialist 23andMe has filed for bankruptcy, prompting the resignation of co-founder and chief executive Anne Wojcicki.
News EMA panel endorses AI for MASH clinical trials PathAI's artificial intelligence tool for diagnosing MASH has become the first to be recommended under the EMA's Qualification Opinion framework.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.